Status:
COMPLETED
The Predictive Value of On-treatment Virological Response for Sustained Virological Response in Chronic Hepatitis C
Lead Sponsor:
Beijing Ditan Hospital
Conditions:
Chronic Hepatitis C
Eligibility:
All Genders
11-75 years
Brief Summary
The efficacy of combination antiviral therapy for chronic hepatitis C is influenced by many factors. Important patient-specific factors include, age, gender, race, body weight. Important virus-specifi...
Detailed Description
297 consecutive patients with chronic hepatitis C who were admitted to hospital or treated as outpatients at Beijing Ditan Hospital were eligible for the study. The diagnosis of chronic hepatitis C wa...
Eligibility Criteria
Inclusion
- Patients with anti-HCV and HCV RNA positive for at least 6 months
Exclusion
- Had a haemoglobin level \<100 g/L
- Neutrophil count \<1.5 x 109/L
- Platelet count \<50 x 109/L
- Decompensated liver cirrhosis or liver disease other than that attributable to chronic hepatitis C
- Co-infected with hepatitis B virus or human immunodeficiency virus
- Had an autoimmune disease, liver tumour, or severe cardiac disease.
Key Trial Info
Start Date :
January 1 2004
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 1 2011
Estimated Enrollment :
297 Patients enrolled
Trial Details
Trial ID
NCT01464008
Start Date
January 1 2004
End Date
September 1 2011
Last Update
September 27 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing Ditan hospital,Capital Medical University
Beijing, Beijing Municipality, China, 100015